- Home
- AIEV vs APRE Comparison
AIEV vs APRE Comparison
Compare AIEV & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIEV
- APRE
- Stock Information
- Founded
- AIEV 2011
- APRE 2006
- Country
- AIEV United States
- APRE United States
- Employees
- AIEV N/A
- APRE N/A
- Industry
- AIEV Blank Checks
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AIEV Finance
- APRE Health Care
- Exchange
- AIEV Nasdaq
- APRE Nasdaq
- Market Cap
- AIEV 11.6M
- APRE 13.5M
- IPO Year
- AIEV N/A
- APRE 2019
- Fundamental
- Price
- AIEV $0.15
- APRE $1.80
- Analyst Decision
- AIEV
- APRE Strong Buy
- Analyst Count
- AIEV 0
- APRE 2
- Target Price
- AIEV N/A
- APRE $15.50
- AVG Volume (30 Days)
- AIEV 1.9M
- APRE 21.0K
- Earning Date
- AIEV 05-15-2025
- APRE 05-13-2025
- Dividend Yield
- AIEV N/A
- APRE N/A
- EPS Growth
- AIEV N/A
- APRE N/A
- EPS
- AIEV N/A
- APRE N/A
- Revenue
- AIEV N/A
- APRE $1,502,581.00
- Revenue This Year
- AIEV N/A
- APRE N/A
- Revenue Next Year
- AIEV N/A
- APRE N/A
- P/E Ratio
- AIEV N/A
- APRE N/A
- Revenue Growth
- AIEV N/A
- APRE 157.63
- 52 Week Low
- AIEV $0.13
- APRE $1.85
- 52 Week High
- AIEV $12.12
- APRE $6.70
- Technical
- Relative Strength Index (RSI)
- AIEV N/A
- APRE 26.70
- Support Level
- AIEV N/A
- APRE $1.85
- Resistance Level
- AIEV N/A
- APRE $2.30
- Average True Range (ATR)
- AIEV 0.00
- APRE 0.16
- MACD
- AIEV 0.00
- APRE -0.01
- Stochastic Oscillator
- AIEV 0.00
- APRE 2.50
About AIEV Thunder Power Holdings Inc. Common Stock
Thunder Power Holdings Inc is engaged in the design and development of high-performance electric vehicles.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.